Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 17/20 | 0.45 |
| ▸ | GUCY1A2 | P33402 | 17/20 | 0.45 |
| ▸ | GUCY1A1 | Q02108 | 17/20 | 0.45 |
| ▸ | GUCY1B1 | Q02153 | 17/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15663482 | 0.91 | PTGER1 (0.51) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1PTGER1 | |
| SCHEMBL15664232 | 0.89 | GUCY1B2 (0.46) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL17224980 | 0.89 | MAPK1 (0.43) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL17224951 | 0.87 | GUCY1B2 (0.41) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1PTGER1 | |
| SCHEMBL15630797 | 0.82 | GUCY1B2 (0.62) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15812416 | 0.82 | GUCY1B2 (0.40) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15663596 | 0.80 | GUCY1B2 (0.50) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15664222 | 0.80 | GUCY1B2 (0.52) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15663508 | 0.80 | GUCY1B2 (0.52) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15664140 | 0.80 | GUCY1B2 (0.48) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3137463-A1 | ENANTIOMERS OF THE N-(2-AMINO-5-FLUORO-2-METHYLPENTYL)-8-[(2,6-DIFLUOROBENZYL)OXY]-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE, AS WELL AS OF THE DI- AND TRIFLUORO DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-08 | — | — | EP | disclosed |
| US-20170057958-A1 | ENANTIOMERS OF THE N-(2-AMINO-5-FLUORO-2-METHYLPENTYL)-8-[(2,6-DIFLUOROBENZYL)OXY]-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE, AS WELL AS OF THE DI- AND TRIFLUORO DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170057958-A1 | ENANTIOMERS OF THE N-(2-AMINO-5-FLUORO-2-METHYLPENTYL)-8-[(2,6-DIFLUOROBENZYL)OXY]-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE, AS WELL AS OF THE DI- AND TRIFLUORO DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170057958-A1 | ENANTIOMERS OF THE N-(2-AMINO-5-FLUORO-2-METHYLPENTYL)-8-[(2,6-DIFLUOROBENZYL)OXY]-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE, AS WELL AS OF THE DI- AND TRIFLUORO DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-02 | — | — | US | disclosed |
| WO-2015165930-A1 | ENANTIOMERS OF THE N-(2-AMINO-5-FLUORO-2-METHYLPENTYL)-8-[(2,6-DIFLUOROBENZYL)OXY]-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE, AS WELL AS OF THE DI- AND TRIFLUORO DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015165930-A1 | ENANTIOMERS OF THE N-(2-AMINO-5-FLUORO-2-METHYLPENTYL)-8-[(2,6-DIFLUOROBENZYL)OXY]-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE, AS WELL AS OF THE DI- AND TRIFLUORO DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057958-A1 | ENANTIOMERS OF THE N-(2-AMINO-5-FLUORO-2-METHYLPENTYL)-8-[(2,6-DIFLUOROBENZYL)OXY]-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE, AS WELL AS OF THE DI- AND TRIFLUORO DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | AADAC, TNNT2, TNNI3 | GUCY1B2 275/4885GUCY1A2 140/4885GUCY1A1 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.